Antegenes
Tartu
About Antegenes
Antegenes’ novel genetic tests assess a patient’s personal cancer risks, and include clinical recommendations for personalized cancer prevention. The tests are based on innovative polygenic risk score technology which helps to clarify a person’s genetic predispositions to cancer. It therefore allows for more accurate prevention and early detection measures – crucial in the fight with cancer. The tests are currently being used to determine the genetic risk for four cancers: breast cancer, prostate cancer, colon cancer, and skin melanoma.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $3.2M
- Funding stage: Seed
- Last round: Grant (Aug 2022)
- Website: antegenes.com
- Phone: +372-5377-8141
Industries & Categories
Biotechnology, Genetics, Health Care
Social Profiles
Canonical: https://fsome.com/organization/antegenes-30234 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.